{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:46:05Z","timestamp":1792201565595,"version":"4.4.0"},"reference-count":113,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.eprac.2024.09.018","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T23:35:15Z","timestamp":1727566515000},"page":"4-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The University of Iowa Neuroendocrine Tumor Clinic"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5312-5972","authenticated-orcid":false,"given":"James R.","family":"Howe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Menda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrikha","family":"Chandrasekharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Bellizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn E.","family":"Quelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Sue","family":"O\u2019Dorisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2024.09.018_bib1","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1073\/pnas.70.3.684","article-title":"Primary structure of somatostatin, a hypothalamic peptide that inhibits the secretion of pituitary growth hormone","volume":"70","author":"Burgus","year":"1973","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eprac.2024.09.018_bib2","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1210\/jcem-68-4-796","article-title":"The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome","volume":"68","author":"Oberg","year":"1989","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2024.09.018_bib3","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eprac.2024.09.018_bib4","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1210\/jcem-70-6-1702","article-title":"Plasma substance-P in neuroendocrine tumors and idiopathic flushing: the value of pentagastrin stimulation tests and the effects of somatostatin analog","volume":"70","author":"Vinik","year":"1990","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2024.09.018_bib5","first-page":"1078","article-title":"Vasoactive intestinal polypeptide-, neurotensin-, substance P-, gastrin-releasing peptide-, calcitonin-, calcitonin gene related peptide-, and somatostatin-like immunoreactivities in human parathyroid glands","volume":"110","author":"Weber","year":"1991","journal-title":"Surgery"},{"key":"10.1016\/j.eprac.2024.09.018_bib6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/MPA.0b013e3181c68d7a","article-title":"Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior","volume":"39","author":"O'Dorisio","year":"2010","journal-title":"Pancreas"},{"key":"10.1016\/j.eprac.2024.09.018_bib7","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1172\/JCI111392","article-title":"Action of gastrin in Guinea pig oxyntic cells. Studies using quantitative cytochemistry","volume":"74","author":"Heldsinger","year":"1984","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.eprac.2024.09.018_bib8","first-page":"781","article-title":"Hyperinsulinism, glucose-dependent insulinotropic polypeptide, and the enteroinsular axis in morbidly obese patients before and after gastric bypass","volume":"100","author":"Sirinek","year":"1986","journal-title":"Surgery"},{"key":"10.1016\/j.eprac.2024.09.018_bib9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-11-0367","article-title":"Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study","volume":"19","author":"Kvols","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.eprac.2024.09.018_bib10","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4158\/EP151172.OR","article-title":"ESG. Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (Elect): a randomized, double-blind, placebo-controlled trial","volume":"22","author":"Vinik","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2024.09.018_bib11","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.2967\/jnumed.116.180984","article-title":"Localization of unknown primary site with (68)Ga-DOTATOC PET\/CT in patients with metastatic neuroendocrine tumor","volume":"58","author":"Menda","year":"2017","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.eprac.2024.09.018_bib12","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","article-title":"90Y-edotreotide for metastatic carcinoid refractory to octreotide","volume":"28","author":"Bushnell","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eprac.2024.09.018_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2024.09.018_bib14","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/MPA.0b013e31819b6441","article-title":"Development of the Norfolk quality of life tool for assessing patients with neuroendocrine tumors","volume":"38","author":"Vinik","year":"2009","journal-title":"Pancreas"},{"key":"10.1016\/j.eprac.2024.09.018_bib15","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.31192","article-title":"Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases","volume":"124","author":"Kim","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.eprac.2024.09.018_bib16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/00000658-195510000-00015","article-title":"Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas","volume":"142","author":"Zollinger","year":"1955","journal-title":"Ann Surg"},{"key":"10.1016\/j.eprac.2024.09.018_bib17","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-X","article-title":"Sms 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action","volume":"31","author":"Bauer","year":"1982","journal-title":"Life Sci"},{"key":"10.1016\/j.eprac.2024.09.018_bib18","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003495-199753040-00009","article-title":"Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly","volume":"53","author":"Gillis","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.eprac.2024.09.018_bib19","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2967\/jnumed.110.075226","article-title":"Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors","volume":"51","author":"Menda","year":"2010","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.eprac.2024.09.018_bib20","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2967\/jnumed.117.202903","article-title":"(90)Y-DOTATOC dosimetry-based personalized peptide receptor radionuclide therapy","volume":"59","author":"Menda","year":"2018","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.eprac.2024.09.018_bib21","first-page":"581","article-title":"Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases","volume":"18","author":"Bushnell","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.eprac.2024.09.018_bib22","first-page":"1556","article-title":"Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors","volume":"44","author":"Bushnell","year":"2003","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.eprac.2024.09.018_bib23","first-page":"35","article-title":"Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment","volume":"19","author":"Bushnell","year":"2004","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.eprac.2024.09.018_bib24","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1023\/A:1011160913619","article-title":"The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study","volume":"12","author":"Waldherr","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eprac.2024.09.018_bib25","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2024.09.018_bib26","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/annonc\/10.suppl_2.S23","article-title":"Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy","volume":"10","author":"Krenning","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eprac.2024.09.018_bib27","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","article-title":"Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors","volume":"23","author":"Kwekkeboom","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eprac.2024.09.018_bib28","first-page":"660","article-title":"Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model","volume":"47","author":"Madsen","year":"2006","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.eprac.2024.09.018_bib29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13550-014-0038-2","article-title":"Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors","volume":"4","author":"Bushnell","year":"2014","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.eprac.2024.09.018_bib30","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/MPA.0b013e318287ce21","article-title":"Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors","volume":"42","author":"Menda","year":"2013","journal-title":"Pancreas"},{"key":"10.1016\/j.eprac.2024.09.018_bib31","first-page":"228","article-title":"Safety and accuracy of (68)Ga-DOTATOC PET\/CT in children and young adults with solid tumors","volume":"7","author":"Abongwa","year":"2017","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eprac.2024.09.018_bib32","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1097\/MPA.0000000000001625","article-title":"Prospective analysis of the impact of 68Ga-DOTATOC positron emission tomography-computerized axial tomography on management of pancreatic and small bowel neuroendocrine tumors","volume":"49","author":"Ghobrial","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.eprac.2024.09.018_bib33","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2967\/jnumed.119.238287","article-title":"The academic NDA: justification, process, and lessons learned","volume":"61","author":"Sunderland","year":"2020","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.eprac.2024.09.018_bib34","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MPA.0b013e3181ebb2a5","article-title":"The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum","volume":"39","author":"Boudreaux","year":"2010","journal-title":"Pancreas"},{"key":"10.1016\/j.eprac.2024.09.018_bib35","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MPA.0b013e3181ebb168","article-title":"NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas","volume":"39","author":"Kulke","year":"2010","journal-title":"Pancreas"},{"key":"10.1016\/j.eprac.2024.09.018_bib36","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MPA.0b013e31828e34a4","article-title":"Consensus guidelines for the management and treatment of neuroendocrine tumors","volume":"42","author":"Kunz","year":"2013","journal-title":"Pancreas"},{"key":"10.1016\/j.eprac.2024.09.018_bib37","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPA.0000000000000846","article-title":"The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American neuroendocrine tumor society","volume":"46","author":"Howe","year":"2017","journal-title":"Pancreas"},{"key":"10.1016\/j.eprac.2024.09.018_bib38","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","article-title":"The North American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors","volume":"46","author":"Strosberg","year":"2017","journal-title":"Pancreas"},{"key":"10.1016\/j.eprac.2024.09.018_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MPA.0000000000001454","article-title":"The North American neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors","volume":"49","author":"Howe","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.eprac.2024.09.018_bib40","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/MPA.0000000000001597","article-title":"The North American neuroendocrine tumor society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors","volume":"49","author":"Halfdanarson","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.eprac.2024.09.018_bib41","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.surg.2006.07.033","article-title":"Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival","volume":"140","author":"Givi","year":"2006","journal-title":"Surgery"},{"key":"10.1016\/j.eprac.2024.09.018_bib42","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1245\/s10434-020-08695-0","article-title":"It may not Be too little or too late: resecting primary small bowel neuroendocrine tumors in the presence of metastatic disease","volume":"27","author":"Howe","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eprac.2024.09.018_bib43","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/SLA.0000000000002809","article-title":"Resection of the primary gastrointestinal neuroendocrine tumor improves survival with or without liver treatment","volume":"270","author":"Lewis","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.eprac.2024.09.018_bib44","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.surg.2018.09.006","article-title":"Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors","volume":"165","author":"Tierney","year":"2019","journal-title":"Surgery"},{"key":"10.1016\/j.eprac.2024.09.018_bib45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/jamaoncol.2017.3326","article-title":"Association of a prophylactic surgical approach to stage IV small intestinal neuroendocrine tumors with survival","volume":"4","author":"Daskalakis","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eprac.2024.09.018_bib46","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00268-002-6630-z","article-title":"Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases","volume":"26","author":"Hellman","year":"2002","journal-title":"World J Surg"},{"key":"10.1016\/j.eprac.2024.09.018_bib47","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/bjs\/znad247","article-title":"Metastatic small bowel neuroendocrine tumours: surgical management of the primary","volume":"110","author":"Howe","year":"2023","journal-title":"Br J Surg"},{"key":"10.1016\/j.eprac.2024.09.018_bib48","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/bjs\/znad248","article-title":"Metastatic small-bowel neuroendocrine tumours: medical management of the primary","volume":"110","author":"Stalberg","year":"2023","journal-title":"Br J Surg"},{"key":"10.1016\/j.eprac.2024.09.018_bib49","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1245\/s10434-018-6676-2","article-title":"The distal predilection of small bowel neuroendocrine tumors","volume":"25","author":"Keck","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eprac.2024.09.018_bib50","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s002680010232","article-title":"Method for dissection of mesenteric metastases in mid-gut carcinoid tumors","volume":"24","author":"Ohrvall","year":"2000","journal-title":"World J Surg"},{"key":"10.1016\/j.eprac.2024.09.018_bib51","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/SLA.0b013e318212c1e2","article-title":"Twenty-three years of the Warshaw operation for distal pancreatectomy with preservation of the spleen","volume":"253","author":"Ferrone","year":"2011","journal-title":"Ann Surg"},{"key":"10.1016\/j.eprac.2024.09.018_bib52","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1245\/s10434-010-1154-5","article-title":"Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis","volume":"17","author":"Mayo","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eprac.2024.09.018_bib53","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/SLA.0b013e3181bdf8cf","article-title":"Hepatic metastases from neuroendocrine tumors with a \"thin slice\" pathological examination: they are many more than you think","volume":"251","author":"Elias","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.eprac.2024.09.018_bib54","first-page":"1091","article-title":"Cytoreductive hepatic surgery for neuroendocrine tumors","volume":"108","author":"McEntee","year":"1990","journal-title":"Surgery"},{"key":"10.1016\/j.eprac.2024.09.018_bib55","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.eprac.2024.09.018_bib56","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.surg.2014.08.009","article-title":"Expanded criteria for carcinoid liver debulking: maintaining survival and increasing the number of eligible patients","volume":"156","author":"Graff-Baker","year":"2014","journal-title":"Surgery"},{"key":"10.1016\/j.eprac.2024.09.018_bib57","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.surg.2015.05.040","article-title":"Liver-directed surgery of neuroendocrine metastases: what is the optimal strategy?","volume":"159","author":"Maxwell","year":"2016","journal-title":"Surgery"},{"key":"10.1016\/j.eprac.2024.09.018_bib58","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.surg.2017.05.030","article-title":"Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors","volume":"163","author":"Morgan","year":"2018","journal-title":"Surgery"},{"key":"10.1016\/j.eprac.2024.09.018_bib59","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.surg.2018.04.070","article-title":"Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs)","volume":"165","author":"Scott","year":"2019","journal-title":"Surgery"},{"key":"10.1016\/j.eprac.2024.09.018_bib60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2967\/jnumed.120.242875","article-title":"Risk of bowel obstruction in patients with mesenteric or peritoneal disease receiving peptide receptor radionuclide therapy","volume":"62","author":"Strosberg","year":"2021","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.eprac.2024.09.018_bib61","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.surg.2013.05.030","article-title":"Neuroendocrine carcinomas: optimal surgery of peritoneal metastases (and associated intra-abdominal metastases)","volume":"155","author":"Elias","year":"2014","journal-title":"Surgery"},{"key":"10.1016\/j.eprac.2024.09.018_bib62","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2967\/jnumed.117.202275","article-title":"Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors","volume":"59","author":"Hope","year":"2018","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.eprac.2024.09.018_bib63","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.diii.2013.07.006","article-title":"Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC?","volume":"95","author":"Oksuz","year":"2014","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.eprac.2024.09.018_bib64","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.2967\/jnumed.119.236935","article-title":"Inflammation-based index and (68)Ga-DOTATOC PET-derived uptake and volumetric parameters predict outcome in neuroendocrine tumor patients treated with (90)Y-DOTATOC","volume":"61","author":"Pauwels","year":"2020","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.eprac.2024.09.018_bib65","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"(177)Lu-Dotatate plus long-acting octreotide versus highdose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eprac.2024.09.018_bib67","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)Lu-dotatate in the phase III NETTER-1 trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eprac.2024.09.018_bib68","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1007\/s00259-017-3678-4","article-title":"Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry","volume":"44","author":"Sundlov","year":"2017","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.eprac.2024.09.018_bib69","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2967\/jnumed.117.193706","article-title":"Dose mapping after endoradiotherapy with (177)Lu-DOTATATE\/DOTATOC by a single measurement after 4 days","volume":"59","author":"Hanscheid","year":"2018","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.eprac.2024.09.018_bib70","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/mp.12886","article-title":"Technical Note: single time point dose estimate for exponential clearance","volume":"45","author":"Madsen","year":"2018","journal-title":"Med Phys"},{"key":"10.1016\/j.eprac.2024.09.018_bib71","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2967\/jnumed.108.058651","article-title":"MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy","volume":"51","author":"Sgouros","year":"2010","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.eprac.2024.09.018_bib72","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13309","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours","volume":"35","author":"Rinke","year":"2023","journal-title":"J\u00a0Neuroendocrinol"},{"key":"10.1016\/j.eprac.2024.09.018_bib73","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13306","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3","volume":"35","author":"Panzuto","year":"2023","journal-title":"J\u00a0Neuroendocrinol"},{"key":"10.1016\/j.eprac.2024.09.018_bib74","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13332","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for appendiceal neuroendocrine tumours (aNET)","volume":"35","author":"Kaltsas","year":"2023","journal-title":"J\u00a0Neuroendocrinol"},{"key":"10.1016\/j.eprac.2024.09.018_bib75","first-page":"327","article-title":"Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome","volume":"2","author":"Moertel","year":"1979","journal-title":"Cancer Clin Trials"},{"issue":"Suppl 5","key":"10.1016\/j.eprac.2024.09.018_bib76","doi-asserted-by":"crossref","first-page":"V223","DOI":"10.1093\/annonc\/mdq192","article-title":"Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Oberg","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eprac.2024.09.018_bib77","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2024.09.018_bib78","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2024.09.018_bib79","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2024.09.018_bib80","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.2022.40.16_suppl.4004","article-title":"A\u00a0randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211)","volume":"40","author":"Kunz","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eprac.2024.09.018_bib81","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1200\/JCO.2019.37.15_suppl.4005","article-title":"Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC)(Alliance A021202)","volume":"37","author":"Bergsland","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eprac.2024.09.018_bib82","first-page":"C39","article-title":"Repeat peptide receptor radionuclide therapy in neuroendocrine neoplasms: a NET center of excellence experience","volume":"98","author":"Grewal","year":"2023","journal-title":"Endocrine Abstracts"},{"key":"10.1016\/j.eprac.2024.09.018_bib83","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.1245\/s10434-022-12100-3","article-title":"Is there a role for surgical resection of grade 3 neuroendocrine neoplasms?","volume":"29","author":"Borbon","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eprac.2024.09.018_bib84","first-page":"C46","article-title":"Peptide receptor radionuclide therapy improves survival in patients who progress after resection of gastroenteropancreatic neuroendocrine tumors","volume":"98","author":"Borbon","year":"2023","journal-title":"Endocrine Abstracts"},{"key":"10.1016\/j.eprac.2024.09.018_bib85","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.humpath.2019.12.002","article-title":"Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?","volume":"96","author":"Bellizzi","year":"2020","journal-title":"Hum Pathol"},{"key":"10.1016\/j.eprac.2024.09.018_bib86","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/MPA.0000000000000082","article-title":"Elevated pancreatic polypeptide levels in pancreatic neuroendocrine tumors and diabetes mellitus: causation or association?","volume":"43","author":"Maxwell","year":"2014","journal-title":"Pancreas"},{"key":"10.1016\/j.eprac.2024.09.018_bib87","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/PAS.0b013e31823d07f3","article-title":"Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting","volume":"36","author":"Korner","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eprac.2024.09.018_bib88","series-title":"AJCC cancer staging manual","author":"Edge","year":"2010"},{"key":"10.1016\/j.eprac.2024.09.018_bib89","series-title":"World Health Organization Classification of Tumours of the Digestive System","first-page":"13","article-title":"Nomenclature and classification of neuroendocrine neoplams of the digestive system","author":"Rindi","year":"2010"},{"key":"10.1016\/j.eprac.2024.09.018_bib90","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/PAS.0000000000000408","article-title":"The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms","volume":"39","author":"Basturk","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eprac.2024.09.018_bib91","series-title":"Classification of tumours of endocrine organs","author":"Lloyd","year":"2017"},{"key":"10.1016\/j.eprac.2024.09.018_bib92","series-title":"WHO Classification of neuroendocrine neoplasms of the digestive system. WHO Classification of tumours Digestive system tumours","first-page":"16","author":"Klimstra","year":"2019"},{"key":"10.1016\/j.eprac.2024.09.018_bib93","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.eprac.2024.09.018_bib94","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/PAP.0000000000000256","article-title":"An algorithmic immunohistochemical approach to define tumor type and assign site of origin","volume":"27","author":"Bellizzi","year":"2020","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.eprac.2024.09.018_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-21-0152","article-title":"The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"29","author":"Venizelos","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.eprac.2024.09.018_bib96","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1126\/science.1152586","article-title":"Clonal integration of a polyomavirus in human Merkel cell carcinoma","volume":"319","author":"Feng","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.eprac.2024.09.018_bib97","article-title":"Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial","volume":"4","author":"D'Angelo","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eprac.2024.09.018_bib98","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.eprac.2024.09.018_bib99","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/gutjnl-2020-322595","article-title":"Non-functional pancreatic neuroendocrine tumours: ATRX\/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX\/PDX1 expression and tumour size","volume":"71","author":"Hackeng","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.eprac.2024.09.018_bib100","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/ng.2821","article-title":"Somatic mutation of CDKN1B in small intestine neuroendocrine tumors","volume":"45","author":"Francis","year":"2013","journal-title":"Nat Genet"},{"issue":"Suppl 3","key":"10.1016\/j.eprac.2024.09.018_bib101","doi-asserted-by":"crossref","first-page":"S1428","DOI":"10.1245\/s10434-014-4351-9","article-title":"Somatic mutations and genetic heterogeneity at the CDKN1B locus in small intestinal neuroendocrine tumors","volume":"22","author":"Crona","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eprac.2024.09.018_bib102","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cancergen.2015.08.003","article-title":"Somatic alterations of CDKN1B are associated with small bowel neuroendocrine tumors","volume":"208","author":"Maxwell","year":"2015","journal-title":"Cancer Genet"},{"key":"10.1016\/j.eprac.2024.09.018_bib103","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1038\/ncomms4518","article-title":"Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids","volume":"5","author":"Fernandez-Cuesta","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.eprac.2024.09.018_bib104","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.humpath.2011.06.011","article-title":"Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors","volume":"43","author":"Dhall","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1016\/j.eprac.2024.09.018_bib105","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1245\/s10434-017-5899-y","article-title":"Increased grade in neuroendocrine tumor metastases negatively impacts survival","volume":"24","author":"Keck","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eprac.2024.09.018_bib106","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/ajcp\/aqaa275","article-title":"Ki-67 proliferation index assessment in gastroenteropancreatic neuroendocrine tumors by digital image analysis with stringent case and hotspot level concordance requirements","volume":"156","author":"Boukhar","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.eprac.2024.09.018_bib107","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/PAS.0b013e3181da0a20","article-title":"PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors","volume":"34","author":"Long","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eprac.2024.09.018_bib108","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/PAP.0b013e3182a2dc67","article-title":"Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry","volume":"20","author":"Bellizzi","year":"2013","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.eprac.2024.09.018_bib109","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.surg.2014.08.008","article-title":"A\u00a0practical method to determine the site of unknown primary in metastatic neuroendocrine tumors","volume":"156","author":"Maxwell","year":"2014","journal-title":"Surgery"},{"key":"10.1016\/j.eprac.2024.09.018_bib110","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1158\/1078-0432.CCR-12-3078","article-title":"CD44 and OTP are strong prognostic markers for pulmonary carcinoids","volume":"19","author":"Swarts","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eprac.2024.09.018_bib111","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/his.13943","article-title":"SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas","volume":"76","author":"Bellizzi","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.eprac.2024.09.018_bib112","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/PAI.0000000000001144","article-title":"p53 as exemplar next-generation immunohistochemical marker: a molecularly informed, pattern-based approach, methodological considerations, and pan-cancer diagnostic applications","volume":"31","author":"Bellizzi","year":"2023","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.eprac.2024.09.018_bib113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004069","article-title":"Reassessment of CXCR4 chemokine receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-2","volume":"3","author":"Fischer","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.eprac.2024.09.018_bib114","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24006931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24006931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T02:01:44Z","timestamp":1736301704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24006931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":113,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1530891X24006931"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.09.018","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The University of Iowa Neuroendocrine Tumor Clinic","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}